A new study finds fewer than 30% of FDA-cleared AI medical devices reported key safety or adverse event data before approval.
Key Details
- 1Study reviewed FDA data for AI/ML devices cleared between 1995 and July 2023.
- 2Out of 691 devices analyzed, 531 were radiology-specific.
- 3Fewer than 30% of devices shared safety or adverse event information prior to clearance.
- 4Authors call for more stringent testing and clearer regulatory standards.
- 5Lack of predefined efficacy and risk standards highlighted as a critical issue.
Why It Matters
Radiology relies heavily on AI devices, making their safety and efficacy crucial to patient care. The study urges tighter oversight and transparency, which could directly impact how radiologists incorporate AI into practice.
Source
Health Imaging
Related News
•Radiology Business
Women's Uncertainty About AI in Breast Imaging May Limit Acceptance
Many women remain unclear about the role of AI in breast imaging, creating hesitation toward its adoption.
•AuntMinnie
Stanford Team Introduces Real-Time AI Safety Monitoring for Radiology
Stanford researchers introduced an ensemble monitoring model to provide real-time confidence assessments for FDA-cleared radiology AI tools.
•AuntMinnie
Experts Call for Stricter FDA Standards in Radiology AI Validation
Dana-Farber experts recommend actionable steps to enhance the rigor and transparency of FDA validation standards for radiology AI software.